Perfluorhexyloctane

WeightAverage: 432.269
Monoisotopic: 432.112266666Chemical FormulaC₁₄H₁₇F₁₃

Perfluorhexyloctane

• 133331-77-8
• MIEBO
• Tetradecane, 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluoro-
• 7VYX4ELWQM
• NOV03, NOV 03
• 1-(perfluorohexyl)octane
• F6H8
• NOV03
• Perfluorohexyloctane

1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane

FDA APPROVED 8/16/2023, Sohonos, To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva
Drug Trials Snapshot

Perfluorohexyloctane is a fluoroalkane that is tetradecane in which all of the hydrogen atoms at positions 1, 2, 3, 4, 5, and 6 have been replaced by fluorine atoms. It is an ophthalmic solution used to treat the signs and symptoms of dry eye disease. It has a role as an ophthalmology drug and a nonionic surfactant. It is a fluorohydrocarbon and a fluoroalkane. It derives from a hydride of a tetradecane.

Perfluorohexyloctane (branded as Evotears, Miebo,^[a] and Novatears, among others) is a medication used for the treatment of dry eye disease.^[4] It is a semifluorinated alkane.^[4]

Perfluorohexyloctane has been available in multiple markets since 2015 under the brand names Evotears and Novatears,^[5] and was additionally approved for medical use in the United States in May 2023 under the brand name Miebo.^[4][6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.^[7]

PATENT

Show 102550100 entries

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US11357738	No	2022-06-14	2036-09-29
US10058615	No	2018-08-28	2033-09-12
US10369117	No	2019-08-06	2033-09-12
US10449164	No	2019-10-22	2033-09-12
US10507132	No	2019-12-17	2037-06-21
US10576154	No	2020-03-03	2033-09-12

SYN

https://www.scientificupdate.com/process-chemistry-articles/not-a-dry-eye-in-the-house

Medical uses

Perfluorohexyloctane is indicated for the treatment of the signs and symptoms of dry eye disease.^[4][8][9]

Availability

Perfluorohexyloctane is sold as an over-the-counter medication under the brand names Evotears and Novatears in multiple countries,^[10] costing around NZ$34.00, A$30, and €30 for a one-month supply.

In the US, perfluorohexyloctane is sold under the brand name Miebo; a prescription is required.

Notes and references

1. ^ /ˈmaɪboʊ/ MY-bow

1. ^ “Notice: Multiple additions to the Prescription Drug List (PDL) [2024-10-18]”. Health Canada. 18 October 2024. Retrieved 25 October 2024.
2. ^ “Miebo product information”. Health Canada. 4 September 2024. Retrieved 27 December 2024.
3. ^ “Regulatory Decision Summary for Miebo”. Drug and Health Products Portal. 4 September 2024. Retrieved 27 December 2024.
4. ^ Jump up to:^{a b c d e} “Miebo- perfluorohexyloctane solution”. DailyMed. 18 May 2023. Retrieved 8 June 2023.
5. ^ “URSAPHARM GmbH and Novaliq GmbH Announce European Partnership Agreement” (Press release). Retrieved 15 February 2024.
6. ^ “Bausch + Lomb and Novaliq Announce FDA Approval of Miebo (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease” (Press release). Bausch + Lomb Corporation. 18 May 2023. Retrieved 8 June 2023 – via Business Wire.
7. ^ New Drug Therapy Approvals 2023 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 10 January 2024. Retrieved 9 January 2024.
8. ^ Ballesteros-Sánchez A, De-Hita-Cantalejo C, Sánchez-González MC, Jansone-Langine Z, de Sotomayor MA, Culig J, et al. (October 2023). “Perfluorohexyloctane in dry eye disease: A systematic review of its efficacy and safety as a novel therapeutic agent”. The Ocular Surface. 30: 254–262. doi:10.1016/j.jtos.2023.10.001. hdl:11441/151762. PMID 37813152. S2CID 263802332.
9. ^ Sheppard JD, Evans DG, Protzko EE (November 2023). “A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution”. The American Journal of Managed Care. 29 (14 Suppl): S251 – S259. doi:10.37765/ajmc.2023.89464. PMID 37930231. S2CID 265032840.
10. ^ “In Australia, NovaTears Eye Drops Are Available on the Pharmaceutical Benefits Scheme (PBS) from Now On” (Press release). Retrieved 15 February 2024.

Further reading

• Azhar A, Taimuri MA, Oduoye MO, Sumbal A, Sheikh A, Iqbal A, et al. (September 2024). “MEIBO (perfluorohexyloctane): a novel approach to treating dry eye disease”. Annals of Medicine and Surgery (2012). 86 (9): 5292–5298. doi:10.1097/MS9.0000000000002322. PMC 11374244. PMID 39239035.

////////Perfluorhexyloctane, Sohonos, APPROVALS 2023, FDA 2023, NOV03, NOV 03, MIEBO, 1-perfluorohexyl)octane, F6H8, NOV03, Perfluorohexyloctane